Abstract: A compound of formula (I), pharmaceutically acceptable salt, solvate or in vivo hydrolysable ester thereof for the treatment of asthma, allergic rhinitis, COPD, inflammatory bowel disease, irritable bowel syndrome, osteoarthritis, osteoporosis, rheumatoid arthritis, psoriasis or cancer.

Abstract: A compound of formula (I), pharmaceutically acceptable salt, solvate or in vivo hydrolysable ester thereof for the treatment of asthma, allergic rhinitis, COPD, inflammatory bowel disease, irritable bowel syndrome, osteoarthritis, osteoporosis, rheumatoid arthritis, psoriasis or cancer.

Abstract: A compound of formula (I), pharmaceutically acceptable salt, solvate or in vivo hydrolysable ester thereof for the treatment of asthma, allergic rhinitis, COPD, inflammatory bowel disease, irritable bowel syndrome, osteoarthritis, osteoporosis, rheumatoid arthritis, psoriasis or cancer.

Abstract: A compound of formula (I), pharmaceutically acceptable salt, solvate or in vivo hydrolysable ester thereof for the treatment of asthma, allergic rhinitis, COPD, inflammatory bowel disease, irritable bowel syndrome, osteoarthritis, osteoporosis, rheumatoid arthritis, psoriasis or cancer.

Abstract: The invention provides piperidine and piperazine derivatives of general formula (I), processes for their preparation, pharmaceutical compositions containing them, a process for preparing the pharmaceutical compositions, and their use in therapy.

Abstract: The invention provides piperidine and piperazine derivatives of general formula (I), processes for their preparation, pharmaceutical compositions containing them, a process for preparing the pharmaceutical compositions, and their use in therapy

Abstract: The invention provides piperidine and piperazine derivatives of general formula (I), processes for their preparation, pharmaceutical compositions containing them, a process for preparing the pharmaceutical compositions, and their use in therapy 1

Abstract: The invention provides certain 1,2,4-triazole-3-thione compounds, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.

Abstract: There are described compounds of formula I,ZCHRCON(--N.dbd.CR.sub.4 R.sub.5)CHR.sub.6 (CH.sub.2).sub.n COY Iwhere the substituents are defined in the disclosure.There are also described methods for making the compounds, formulations containing them and their use, e.g. as antihypertensives.

Abstract: There are described compounds of formula I, ##STR1## in which X is O, S or N--R.sub.7,each Y, which may be the same or different, is H, OH, alkyl C1-C8, alkoxy C1-C8 or halogen,n is an integer from 1 to 4 inclusive,R and R.sub.1, which may be the same or different, are each H; alkanoyl C2-C8 or a group R.sub.4 in which R.sub.4 is alkyl C1-C8 optionally substituted by phenyl; or is cycloalkyl C5 or C6; or is a group of formula XVI, ##STR2## in which W and Z, which may be the same or different, are each H, OH, alkoxy C1-C8, phenyl-alkoxy C7 to C10, alkyl C1-C8, halogen, --NR.sub.2 R.sub.3, --COOR.sub.2, NO.sub.2, alkanoyloxy C2-C8, or --OCH.sub.2 CH.sub.2 NR.sub.2 R.sub.3, andR.sub.2, R.sub.3 and R.sub.7, which may be the same or different, are each H or alkyl C1-C8,provided that when X is N--R.sub.7 and R is H, then R.sub.1 is not (a) H when any Y groups are H, alkyl C1-C8, alkoxy C1-C8 or halogen, or (b) unsubstituted phenyl when all Y groups are H,and pharmaceutically acceptable salts thereof.